The appointment is planned to support the company's next phase of growth in the US
Metrion Biosciences, a contract research and drug discovery company, has announced the appointment of Dr Rory Curtis as VP of US Commercial Operations. The appointment represents the next phase in the company’s expansion plans and business growth, it says.
Curtis is based in Buffalo, NY, and will be responsible for the company’s business development operations throughout the United States, including supporting and expanding its existing client base and leading the development of business opportunities in the ion channel field.
Curtis spent 25 years in the management of drug discovery projects at Regeneron, Millennium, Elixir and Cubist Pharmaceuticals. He was responsible for the ion channel discovery platform at Millennium and the TRPA1 program at Cubist, which yielded a Phase I clinical candidate. In 2015, he moved into contract research operations and sales with AMRI (now Curia) and the Hauptman-Woodward Institute.
Nick Foster, CCO, Metrion Biosciences, said: “I am very pleased to welcome Rory to Metrion. Engaging with and supporting our clients in their research is Metrion’s top priority; Rory’s background and extensive experience enhances our ability to provide local support in the United States.”
Dr Rory Curtis, VP US Commercial Operations, Metrion Biosciences, said: “Metrion’s expansion in the North American market is an exciting phase in the development of the business. I am looking forward to joining the team at this pivotal stage and supporting Metrion’s goal to become the leading global ion channel services provider.”